BIOMARIN PHARMACEUTICAL INC Marketable Securities, Unrealized Gain (Loss)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Marketable Securities, Unrealized Gain (Loss) of $2.30 million for the 12-month period ending 2016-12-31, per its 10-Q filed 2017-10-31.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2017-10-31
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for the quarter ending 2016-12-31 was -$2.00M.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for the quarter ending 2016-09-30 was $2.60M.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for the quarter ending 2016-06-30 was -$1.10M.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for the quarter ending 2016-03-31 was $2.80M, a 90.44% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for fiscal 2015 was $12.70M, a 30.60% decline from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for fiscal 2014 was $18.30M, a 81.19% increase from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for fiscal 2013 was $10.10M, a 10000.00% increase from fiscal 2012.
- BIOMARIN PHARMACEUTICAL INC marketable securities, unrealized gain (loss) for fiscal 2012 was $100.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$2.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2017-10-31 | $600.00K derived: sum of 2 quarters · filed 2017-10-31 | -$500.00K derived: sum of 3 quarters · filed 2017-10-31 | $2.30M 10-Q · filed 2017-10-31 |
| 2016-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.50M derived: sum of 2 quarters · filed 2016-11-03 | $4.30M 10-Q · filed 2016-11-03 | $1.00M derived: sum of 4 quarters · filed 2017-02-27 |
| 2016-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $1.70M 10-Q · filed 2016-08-08 | -$1.60M derived: sum of 3 quarters · filed 2017-02-27 | -$10.30M derived: sum of 4 quarters · filed 2017-02-27 |
| 2016-03-31 | $2.80M 10-Q · filed 2016-05-02 | -$500.00K derived: sum of 2 quarters · filed 2017-02-27 | -$9.20M derived: sum of 3 quarters · filed 2017-02-27 | -$13.80M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$12.00M derived: sum of 2 quarters · filed 2017-02-27 | -$16.60M derived: sum of 3 quarters · filed 2017-02-27 | $12.70M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$8.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$13.30M derived: sum of 2 quarters · filed 2015-11-02 | $16.00M 10-Q · filed 2015-11-02 | $15.10M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-06-30 | -$4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $24.70M 10-Q · filed 2015-08-05 | $23.80M derived: sum of 3 quarters · filed 2016-02-29 | $29.00M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-03-31 | $29.30M 10-Q · filed 2015-05-05 | $28.40M derived: sum of 2 quarters · filed 2016-02-29 | $33.60M derived: sum of 3 quarters · filed 2016-02-29 | $35.50M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $4.30M derived: sum of 2 quarters · filed 2016-02-29 | $6.20M derived: sum of 3 quarters · filed 2016-02-29 | $18.30M 10-K · filed 2016-02-29 |
| 2014-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $7.10M derived: sum of 2 quarters · filed 2014-10-28 | $19.20M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $14.00M 10-Q · filed 2014-07-31 | ||
| 2014-03-31 | $12.10M 10-Q · filed 2014-05-02 | |||
| 2013-12-31 | $10.10M 10-K · filed 2015-03-02 | |||
| 2012-12-31 | $100.00K 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |